ライフサイエンスコーパス: rhabdomyosarcoma

1 tizer for the clinical treatment of alveolar rhabdomyosarcoma.

2 rognosis for invasive or metastatic alveolar rhabdomyosarcoma.

3 essential component of therapy for alveolar rhabdomyosarcoma.

4 therapeutic targets for high-risk embryonal rhabdomyosarcoma.

5 fusion gene status to risk stratify alveolar rhabdomyosarcoma.

6 ation of dystrophies to the childhood cancer rhabdomyosarcoma.

7 anisation of the fused landscape in alveolar rhabdomyosarcoma.

8 ites and associated target genes in alveolar rhabdomyosarcoma.

9 evaluation of agents against this aggressive rhabdomyosarcoma.

10 expressed myogenic markers, consistent with rhabdomyosarcoma.

11 associated with the development of alveolar rhabdomyosarcoma.

12 ll leukemia, pancreatic cancer, melanoma and rhabdomyosarcoma.

13 m his father for the treatment of metastatic rhabdomyosarcoma.

14 the pediatric solid tumors, osteosarcoma and rhabdomyosarcoma.

15 lls from a common pediatric cancer, alveolar rhabdomyosarcoma.

16 PDGFR-A as a therapeutic target in alveolar rhabdomyosarcoma.

17 veloped tumors including medulloblastoma and rhabdomyosarcoma.

18 nd irinotecan is highly active in metastatic rhabdomyosarcoma.

19 subtype of the human skeletal muscle tumor, rhabdomyosarcoma.

20 ric patients with newly diagnosed metastatic rhabdomyosarcoma.

21 rk with critical therapeutic implications in rhabdomyosarcoma.

22 converted to a tumorigenic state that mimics rhabdomyosarcoma.

23 r testing in intermediate risk patients with rhabdomyosarcoma.

24 a new strategy to control the metastasis of rhabdomyosarcoma.

25 ved significantly, especially for metastatic rhabdomyosarcoma.

26 06B-BRAF), and a novel PAX3-GLI2 fusion in a rhabdomyosarcoma.

27 samples also confirmed their specificity to rhabdomyosarcoma.

28 and tumor and bone marrow biopsies disclosed rhabdomyosarcoma.

29 d and proliferative phenotypes for embryonal rhabdomyosarcoma.

30 ' tumour, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.

31 cause cancer, for example, breast cancer or rhabdomyosarcoma.

32 histopathology concluded the tissue to be a rhabdomyosarcoma.

33 ncers, but little is known about its role in rhabdomyosarcoma.

34 holds promise for the treatment of alveolar rhabdomyosarcoma.

35 contributes to the differentiation defect in rhabdomyosarcomas.

36 he contribution of two microRNAs (miRNAs) in rhabdomyosarcomas.

37 role for these miRNAs in the development of rhabdomyosarcomas.

38 rs that resembled the human form of alveolar rhabdomyosarcoma, a cancer associated with poor prognosi

39 Rhabdomyosarcoma, a cancer of skeletal muscle lineage, i

40 y tumour (head and neck anaplastic embryonal rhabdomyosarcoma), all patients were alive at the time o

41 KCiota is functionally important in alveolar rhabdomyosarcoma anchorage-independent growth and tumor-

42 as single agents in both zebrafish embryonal rhabdomyosarcoma and a human cell line of rhabdomyosarco

43 fic and tissue-restricted gene expression in rhabdomyosarcoma and a second comprising a novel RAS-ind

44 evant distinction in PDGF signaling in human rhabdomyosarcoma and also suggests continued exploration

45 atients with first relapse or progression of rhabdomyosarcoma and an unfavorable prognosis were rando

46 ul reagent for studies of myasthenia gravis, rhabdomyosarcoma and arthrogryposis multiplex congenita

47 All mice exhibited rhabdomyosarcoma and basal cell carcinoma; 40% also deve

48 cell lines, independent of lineage (alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma), are pa

49 ced complete remissions in one model each of rhabdomyosarcoma and EWS, and in three of four osteosarc

50 med whole-genome and RNA sequencing on human rhabdomyosarcoma and identified RAS mutations and oxidat

51 the protein level in primary EFT but not in rhabdomyosarcoma and neuroblastoma, and EFT cells exhibi

52 ormed cells from these tissue types, such as rhabdomyosarcoma and osteosarcoma.

53 ed malignant cardiac tumors with features of rhabdomyosarcoma and the capacity to metastasize.

54 ng allows improved diagnosis of experimental rhabdomyosarcoma and therefore might influence clinical

55 carcinoma and pediatric malignancies such as rhabdomyosarcoma and Wilms' tumor.

56 pitulate gene-expression signatures of human rhabdomyosarcomas and identified a cluster of genes that

57 ctive target for therapeutic intervention in rhabdomyosarcomas and other tumors that amplify and/or o

58 occur in pediatric patients (Ewing sarcoma, rhabdomyosarcoma), and just as clearly, adjuvant chemoth

59 expression of HOTS inhibits Wilms, rhabdoid, rhabdomyosarcoma, and choriocarcinoma tumor cell growth,

60 When tested in human osteosarcoma, rhabdomyosarcoma, and Ewing's sarcoma stem cells, the ne

61 ipoliovirus immunity (n = 17) on Vero, human rhabdomyosarcoma, and human epidermoid carcinoma 2 cells

62 Notably, Ewing's sarcoma, rhabdomyosarcoma, and neuroblastoma are more responsive

63 icular germ-cell tumors, in 2 of 5 embryonal rhabdomyosarcomas, and in 1 of 266 epithelial ovarian an

64 Rhabdomyosarcomas are characterized by expression of myo

65 Although adult rhabdomyosarcomas are very rare, this case highlights th

66 age (alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma), are particularly sensitive to the ind

67 essful purification of RNA from the alveolar rhabdomyosarcoma (ARMS) cancer cell line, with 3.5-fold

68 ariant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival of <30%.

69 Alveolar rhabdomyosarcoma (ARMS) is a devastating pediatric disea

70 Alveolar rhabdomyosarcoma (ARMS) is a muscle-derived childhood tu

71 Alveolar rhabdomyosarcoma (aRMS) is an aggressive childhood cance

72 Alveolar rhabdomyosarcoma (aRMS) is an aggressive myogenic childh

73 Alveolar rhabdomyosarcoma (ARMS) is an aggressive pediatric muscl

74 Alveolar rhabdomyosarcoma (aRMS) is an aggressive sarcoma of skel

75 The highly aggressive muscle cancer alveolar rhabdomyosarcoma (ARMS) is one of the most common soft t

76 e 2;13 chromosomal translocation in alveolar rhabdomyosarcoma (ARMS), a cancer associated with the sk

77 velopment and is a key component in alveolar rhabdomyosarcoma (ARMS), a childhood solid muscle tumor.

78 t the concept into use, we selected alveolar rhabdomyosarcoma (ARMS), a myogenic pediatric cancer who

79 transcription factor, which induces alveolar rhabdomyosarcoma (aRMS), an aggressive cancer of skeleta

80 dismal for patients with metastatic alveolar rhabdomyosarcoma (aRMS), where the chimeric transcriptio

81 Among RMS subtypes, alveolar rhabdomyosarcoma (ARMS), which is characterized by the p

82 Alveolar rhabdomyosarcomas (ARMS) are highly malignant soft-tissu

83 Alveolar rhabdomyosarcomas (ARMS) escape terminal differentiation

84 In contrast, alveolar rhabdomyosarcomas (ARMS) have fewer genetic lesions over

85 protein is present in a majority of alveolar rhabdomyosarcomas associated with increased aggressivene

86 nd young adults (age range, 1-18 years) with rhabdomyosarcoma at two institutions (1999-2009) with re

87 disrupting effects in a tumor model of liver rhabdomyosarcomas at 15 mg/kg intravenous dosage.

88 nd mTOR-signaling pathways are implicated in rhabdomyosarcoma biology, and hence are promising therap

89 ferentiation and tumorigenesis, can classify rhabdomyosarcomas by clinical subtype, and can predict p

90 nic differentiation can be induced in the RD rhabdomyosarcomas by increasing the abundance of MyoD:E-

91 The childhood cancer embryonal rhabdomyosarcoma can arise in tissue without skeletal mu

92 Oral rhabdomyosarcoma can develop insidiously.

93 RI/II confirmed TNFRI-AlbudAb potency, human rhabdomyosarcoma cell line KYM-1D4 cytotoxicity, and hum

94 nd is stereospecific because exposure of the rhabdomyosarcoma cell line RD to the L-erythro and DL-th

95 , we developed two resistant models from the rhabdomyosarcoma cell line Rh41: Rh41-807R, with acquire

96 ditions, while in a patient-derived alveolar rhabdomyosarcoma cell line, harbouring the diagnostic t(

97 ifically bind on the cell surface of a human rhabdomyosarcoma cell line, RD.

98 DGFC was observed in the sunitinib-sensitive rhabdomyosarcoma cell line.

99 ression in ERMS cells was confirmed in human rhabdomyosarcoma cell lines and prompted further analysi

100 en in human ARMS tumor tissue, as both human rhabdomyosarcoma cell lines and tissue microarrays showe

101 pression and knockdown of GPC5 expression in rhabdomyosarcoma cell lines increased and decreased cell

102 We present data showing that rhabdomyosarcoma cell lines, independent of lineage (alv

103 ed the presence of fetal AChR on a number of rhabdomyosarcoma cell lines.

104 specimens that were comparable with those in rhabdomyosarcoma cell lines.

105 gth E12 robustly restores differentiation in rhabdomyosarcoma cells and broadly suppresses multiple i

106 th genes overexpressed in PAX3-FKHR-positive rhabdomyosarcoma cells and tumors.

107 diation therapy in the treatment of alveolar rhabdomyosarcoma cells and xenografts.

108 inhibition of PI3K-mTOR-AKT pathway in Rh30 rhabdomyosarcoma cells attenuated ICL-induced activation

109 oculated i.m. with the RH30-L cells had more rhabdomyosarcoma cells in the bone marrow and lung after

110 use Kras; p16p19(null) sarcomas and of human rhabdomyosarcoma cells in vitro and in vivo.

111 The injection of rhabdomyosarcoma cells led to intraperitoneal tumor grow

112 oma xenograft to radiotherapy and sensitized rhabdomyosarcoma cells to the DNA interstrand cross-link

113 Both HT1080 cells overexpressing hTDP1 and rhabdomyosarcoma cells with elevated levels of hTdp1 wer

114 e million alveolar (Rh30) and embryonal (RD) rhabdomyosarcoma cells with stably transfected mCherry a

115 blasts or HeLa cells) or by necrosis (in Rh4 rhabdomyosarcoma cells).

116 We found that in rhabdomyosarcoma cells, LIF stimulates the following: (a

117 Once introduced into rhabdomyosarcoma cells, miR-22 decreased cell proliferat

118 is in both primary human muscle cells and RD rhabdomyosarcoma cells, we demonstrate that MyoD binds i

119 ble in the EV71 genome for eight passages on rhabdomyosarcoma cells.

120 hat prevent MyoD activity in human embryonal rhabdomyosarcoma cells.

121 receptor (LIF-R) axis affects the biology of rhabdomyosarcoma cells.

122 ession pattern as PAX3-FOXO1 are specific to rhabdomyosarcoma cells.

123 bryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma constitute the two major subtypes and e

124 tion of miR-1 and miR-133a into an embryonal rhabdomyosarcoma-derived cell line is cytostatic, thereb

125 mosomal translocation that leads to alveolar rhabdomyosarcoma development generates a novel TAD that

126 molecule antagonists to treat ARMS and other rhabdomyosarcomas driven by PAX3-FOXO1A.

127 des two histolopathologic subtypes: alveolar rhabdomyosarcoma, driven by the fusion protein PAX3-FOXO

128 Thus, MYOD1 p.Leu122Arg defines a subset of rhabdomyosarcomas eligible for high-risk protocols and t

129 ing of tumour-propagating cells in embryonal rhabdomyosarcoma, emergence of clonal dominance in T-cel

130 Embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma co

131 Embryonal Rhabdomyosarcoma (ERMS) and Undifferentiated Pleomorphic

132 , or gross residual (orbital only) embryonal rhabdomyosarcoma (ERMS) had 5-year failure-free survival

133 Embryonal rhabdomyosarcoma (ERMS) is a common pediatric malignancy

134 Embryonal rhabdomyosarcoma (ERMS) is a devastating cancer with spe

135 Embryonal rhabdomyosarcoma (ERMS) is an aggressive pediatric sarco

136 Embryonic rhabdomyosarcoma (ERMS) is the most common soft-tissue t

137 tein PAX3-FOXO1 or PAX7-FOXO1, and embryonal rhabdomyosarcoma (ERMS), which is genetically heterogene

138 YAP1 activity is elevated in human embryonal rhabdomyosarcoma (ERMS).

139 patients with subset-one low-risk embryonal rhabdomyosarcoma (ERMS; stage 1/2 group I/II ERMS or sta

140 d with intermediate- and high-risk embryonal rhabdomyosarcomas (ERMS).

141 ymphoma), solid malignancies (neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, and osteosarcoma), and

142 tumors that affect children, particularly in rhabdomyosarcoma, Ewing sarcoma, and other round cell sa

143 of 61 (13%); osteosarcoma, two of 20 (10%); rhabdomyosarcoma, four of 26 (15%); and other sarcomas,

144 Rhabdomyosarcoma frequently infiltrates bone marrow and

145 e signature we determined could discriminate rhabdomyosarcoma from muscle, revealing a subset of musc

146 Our initial studies of rhabdomyosarcoma gene expression for patients enrolled i

147 In rhabdomyosarcoma, genitourinary site and embryonal histo

148 Rhabdomyosarcoma has two major histologic subtypes, embr

149 therapeutic options for the pediatric cancer rhabdomyosarcoma have not improved significantly, especi

150 Rhabdomyosarcomas have not been observed previously in n

151 In rhabdomyosarcoma, ILK and platelet-derived growth factor

152 hepatoblastoma developing in 6 children and rhabdomyosarcoma in 10 children.

153 f origin for Sonic Hedgehog-driven embryonal rhabdomyosarcoma in an adipocyte-restricted conditional

154 ostic tests and imaging required to identify rhabdomyosarcoma in any body site.

155 mplex diagnosis, assessment and treatment of rhabdomyosarcoma in children.

156 thentically recapitulates the progression of rhabdomyosarcoma in humans.

157 re most similar to well-differentiated human rhabdomyosarcoma in terms of gene expression.

158 Here, we have generated models of rhabdomyosarcoma in the zebrafish by inducing oncogenic

159 tions and metastatic progression of alveolar rhabdomyosarcomas in humans, we found by immunoblotting

160 Major subtypes of rhabdomyosarcoma include alveolar (ARMS) and embryonal (

161 Rhabdomyosarcoma includes two histolopathologic subtypes

162 copy number and gene expression analyses of rhabdomyosarcomas indicated that GPC5 was the only gene

163 Rhabdomyosarcoma is a malignant neoplasm of primitive me

164 Rhabdomyosarcoma is a pediatric malignancy thought to ar

165 Rhabdomyosarcoma is a pediatric tumor of skeletal muscle

166 Rhabdomyosarcoma is a primitive neoplasm with a poorly u

167 Rhabdomyosarcoma is a rare childhood cancer that affects

168 Rhabdomyosarcoma is a rare, soft tissue malignancy, diag

169 Rhabdomyosarcoma is a soft-tissue sarcoma with molecular

170 Alveolar rhabdomyosarcoma is an aggressive pediatric cancer exhib

171 Alveolar rhabdomyosarcoma is an aggressive skeletal muscle cancer

172 The diagnosis of tumor recurrence in rhabdomyosarcoma is extremely challenging and could be i

173 ock in the childhood muscle cancer embryonal rhabdomyosarcoma is often thought to hold promise as an

174 The 5-year survival for localized rhabdomyosarcoma is over 70%, but only 30% for patients

175 Oral rhabdomyosarcoma is rare and accounts for only 0.04% of

176 Rhabdomyosarcoma is the most common sarcoma in children

177 Rhabdomyosarcoma is the most common soft tissue sarcoma

178 Rhabdomyosarcoma is the most common soft tissue sarcoma

179 erapy, patients with a histologic variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARM

180 omas, suppressed differentiation of myogenic rhabdomyosarcoma lines generated from Hip1+/- and Ptch1+

181 Rhabdomyosarcoma lines with elevated human Tdp1 levels a

182 Rhabdomyosarcomas may therefore arise from cells which d

183 ipoma, leiomyoma, haemangioma) or malignant (rhabdomyosarcoma, melanotic neuroectodermal tumour of in

184 evidence that the LIF-LIF-R axis may direct rhabdomyosarcoma metastasis.

185 logic activities linked to PDGF signaling in rhabdomyosarcoma models and human sample collections.

186 In syngeneic murine rhabdomyosarcoma models, we found that M3-9-M (MHC I hig

187 to validate PET/MR imaging in a disseminated rhabdomyosarcoma mouse model.

188 shock of whole zebrafish embryos, including rhabdomyosarcoma, myeloproliferative disorder, intestina

189 ted satellite cells gave rise to pleomorphic rhabdomyosarcomas (MyoD-, Myogenin- and Desmin-positive)

190 ed in patients with medulloblastoma (n = 4), rhabdomyosarcoma (n = 1), neuroblastoma (n = 1), and ger

191 ant peripheral-nerve sheath tumor (n = 7), 0 rhabdomyosarcoma (n = 2), and three synovial sarcomas (n

192 number of additional malignancies, including rhabdomyosarcoma, neuroblastoma, anaplastic large cell l

193 onal study trials exist for the treatment of rhabdomyosarcoma, only very limited information is given

194 age 21 years with newly diagnosed metastatic rhabdomyosarcoma or undifferentiated sarcoma received wi

195 ne can lead to complete response in multiple rhabdomyosarcoma orthotopic patient-derived xenografts t

196 mphomas, astrocytomas, Ewing's sarcomas, and rhabdomyosarcomas (p<0.0001 in all cases), and osteosarc

197 d the biological relevance of these genes in rhabdomyosarcoma pathogenesis.

198 cation that is the foundation of all present rhabdomyosarcoma protocols developed by the Children's O

199 inations of the above were investigated in a rhabdomyosarcoma rat tumor model (n = 113).

200 greatly reduced the growth of two different rhabdomyosarcoma (RD embryonal P = 0.00008; Rh30 alveola

201 g passage of the prototype strain, Nancy, on rhabdomyosarcoma (RD) cells, which express DAF but very

202 on (H37R) was required for mEV71 recovery on rhabdomyosarcoma (RD) cells.

203 otherapy, the overall survival for childhood rhabdomyosarcoma remains approximately 60%.

204 Our studies indicate that rhabdomyosarcomas represent an arrested progress through

205 The accurate detection of rhabdomyosarcoma requires high soft-tissue contrast prov

206 ene expression profiles of 101 primary human rhabdomyosarcomas revealed elevated PDGF-C and -D expres

207 cated in drug-sensitive and -resistant human rhabdomyosarcoma Rh30 cells, suggesting that our finding

208 )-stimulated F-actin reorganization in human rhabdomyosarcoma (Rh30), Ewing sarcoma (Rh1), glioblasto

209 Some patients with rhabdomyosarcoma (RMS) achieve less than a complete resp

210 eous development of muscle-derived embryonal rhabdomyosarcoma (RMS) after 1 year of age.

211 uding gastrointestinal stromal tumor (GIST), rhabdomyosarcoma (RMS) and leiomyosarcoma (LMS), feature

212 OR) pathway is often aberrantly activated in rhabdomyosarcoma (RMS) and represents a promising therap

213 Using pediatric rhabdomyosarcoma (RMS) as a paradigm to elucidate the me

214 nely lost in advanced, poorly differentiated rhabdomyosarcoma (RMS) but characteristically expressed

215 GFBP-6 was found to promote the migration of rhabdomyosarcoma (RMS) cells in an IGF-independent manne

216 ntial element for the growth and survival of rhabdomyosarcoma (RMS) cells using a bar-coded, tetracyc

217 Here, we show that human rhabdomyosarcoma (RMS) cells, but not several other canc

218 apid cell death and tumor regression in some rhabdomyosarcoma (RMS) cells.

219 r tumors from diagnostic biopsies of primary rhabdomyosarcoma (RMS) contain relevant prognostic infor

220 e for cilia in normal muscle development and rhabdomyosarcoma (RMS) has not been explored.

221 Rhabdomyosarcoma (RMS) in children occurs as two major h

222 Rhabdomyosarcoma (RMS) is a childhood cancer originating

223 Rhabdomyosarcoma (RMS) is a common soft-tissue sarcoma o

224 Rhabdomyosarcoma (RMS) is a malignancy of muscle myoblas

225 Rhabdomyosarcoma (RMS) is a morphologically and clinical

226 Rhabdomyosarcoma (RMS) is a pediatric malignacy of muscl

227 Rhabdomyosarcoma (RMS) is an aggressive childhood soft t

228 Rhabdomyosarcoma (RMS) is an aggressive skeletal muscle-

229 Rhabdomyosarcoma (RMS) is an aggressive soft tissue canc

230 Rhabdomyosarcoma (RMS) is the commonest soft-tissue sarc

231 Rhabdomyosarcoma (RMS) is the most common soft tissue sa

232 Rhabdomyosarcoma (RMS) is the most common soft tissue sa

233 Rhabdomyosarcoma (RMS) is the most common soft tissue sa

234 Rhabdomyosarcoma (RMS) is the most common soft tissue sa

235 Rhabdomyosarcoma (RMS) is the most commonly occurring ty

236 Rhabdomyosarcoma (RMS) is the most frequent soft tissue

237 The outcome for localized rhabdomyosarcoma (RMS) or undifferentiated sarcoma (UDS)

238 ntify novel signaling pathways necessary for rhabdomyosarcoma (RMS) survival, we performed a loss-of-

239 e outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincri

240 e poor prognosis of metastatic and recurrent rhabdomyosarcoma (RMS) under the current regimen of poly

241 Rhabdomyosarcoma (RMS) without local invasion (T1) had a

242 In rhabdomyosarcoma (RMS), a pediatric soft-tissue sarcoma

243 iple tumor types including synovial sarcoma, rhabdomyosarcoma (RMS), and colon cancer.

244 Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 yea

245 n aggressive metastatic disease in pediatric rhabdomyosarcoma (RMS), irrespective of histological sub

246 atients with incompletely resected embryonal rhabdomyosarcoma (RMS), undifferentiated sarcoma, and so

247 g for new strategies to trigger apoptosis in rhabdomyosarcoma (RMS), we investigated the effect of tw

248 ession and underlying genetic aberrations in rhabdomyosarcoma (RMS), with special attention to clinic

249 me of the advances in the way we think about rhabdomyosarcoma (RMS).

250 ggest poor outcome in children with relapsed rhabdomyosarcoma (RMS).

251 f the risk-based treatment stratification in rhabdomyosarcoma (RMS).

252 therapy for children with intermediate-risk rhabdomyosarcoma (RMS).

253 sease-including the childhood muscle cancer, rhabdomyosarcoma (RMS).

254 icularly in patients with PAX3-FKHR-positive rhabdomyosarcoma (RMS).

255 nt with proton radiotherapy in children with rhabdomyosarcoma (RMS).

256 Rhabdomyosarcomas (RMS) are the most frequent soft-tissu

257 from P2 MCMV-infected mice were pleomorphic rhabdomyosarcomas (RMS) harboring MCMV DNA, RNA, and pro

258 Rhabdomyosarcoma samples showed overexpression of PDGFRa

259 [a non-small-cell lung cancer (NSCLC) and a rhabdomyosarcoma] showed expression of highly phosphoryl

260 , 6.21 cases per 1 million person-years) and rhabdomyosarcoma (standardized incidence ratio, 2.62; 95

261 For Intergroup Rhabdomyosarcoma Study (IRS) IV patients with group III

262 rom the Children's Oncology Group Intergroup Rhabdomyosarcoma Study (IRS) IV, D9502 and D9803, with 1

263 overall survival rates of 95% on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III/IV.

264 Intergroup Rhabdomyosarcoma Study Group (IRSG) studies III and IV s

265 Patient data from the Intergroup Rhabdomyosarcoma Study Group and the Children's Oncology

266 oup, Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, and the National Wilms Tum

267 system), and post-surgical stage (Intergroup Rhabdomyosarcoma Study system).

268 3/FOXO1 and PAX7/FOXO1 positive), Intergroup Rhabdomyosarcoma Study TNM stage, and age showed a signi

269 Sixteen IRS (Intergroup Rhabdomyosarcoma Study) III and IV patients had locoregi

270 ediate-risk RMS enrolled onto the Intergroup Rhabdomyosarcoma Study-IV and the Children's Oncology Gr

271 in representative cell lines from each major rhabdomyosarcoma subtype (embryonal and alveolar).

272 eep miRNA profiling of the three major human rhabdomyosarcoma subtypes, along with cell lines and nor

273 ts of miR-1 and miR-133a are up-regulated in rhabdomyosarcomas, suggesting a causative role for these

274 ue in patients with relapsed Wilms tumor and rhabdomyosarcoma suggests that some patients may benefit

275 ue in patients with relapsed Wilms tumor and rhabdomyosarcoma suggests that some patients may benefit

276 is expressed in a subset of mouse and human rhabdomyosarcomas, suppressed differentiation of myogeni

277 p16p19(null) sarcomas and in 26-50% of human rhabdomyosarcomas surveyed.

278 specifically focus on embryonal and alveolar rhabdomyosarcoma, synovial sarcoma, and adult soft tissu

279 al rhabdomyosarcoma and a human cell line of rhabdomyosarcoma that harbored activated mutations in NR

280 ons of clinical studies describing a type of rhabdomyosarcoma that resembles acute leukemia.

281 region is reported in many tumors, including rhabdomyosarcomas that are primarily pediatric sarcomas

282 rexpression of the nuclear receptor NR4A1 in rhabdomyosarcomas that is sufficient to drive high expre

283 gested as potential targets for treatment of rhabdomyosarcoma, the most common soft tissue sarcoma in

284 se results point to the promise of enhancing rhabdomyosarcoma therapy using miRNAs as agents that med

285 A metastatic rhabdomyosarcoma to the eye was considered unlikely beca

286 Rhabdomyosarcoma today has an overall survival of 70%, d

287 ), a microtubule inhibitor currently used in rhabdomyosarcoma treatment regimens, resulted in a combi

288 showed a large variation in IGF-IR levels in rhabdomyosarcoma tumor specimens that were comparable wi

289 AX3-FKHR translocation to the development of rhabdomyosarcoma tumors has been further elucidated.

290 A diagnosis of embryonal rhabdomyosarcoma was made.

291 A KRAS(G12D)-induced zebrafish embryonal rhabdomyosarcoma was then used to assess the therapeutic

292 pping region of amplification at 13q31-32 in rhabdomyosarcomas was defined as containing two genes: G

293 rcoma Study (IRS) IV patients with group III rhabdomyosarcoma, we assessed whether reported response

294 o molecular subtypes of the pediatric cancer rhabdomyosarcoma, we show that an exhaustive iterative s

295 Increased risks of hepatoblastoma and rhabdomyosarcoma were detected, but the absolute risks w

296 We present a rare case of an adult rhabdomyosarcoma which illustrates the importance of mag

297 We established a unique model of metastatic rhabdomyosarcoma with a high frequency of tumor occurren

298 inical samples of the skeletal muscle cancer rhabdomyosarcoma, with the highest expression found in t

299 ficantly enhanced sensitivity of a pediatric rhabdomyosarcoma xenograft to radiotherapy and sensitize

300 ere evaluated against EWS, osteosarcoma, and rhabdomyosarcoma xenografts.